Drug Type Small molecule drug |
Synonyms + [2] |
Action agonists, antagonists |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists), M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M2 receptor antagonists(Muscarinic acetylcholine receptor M2 antagonists) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Australia (04 Feb 2011), |
Regulation- |
Molecular FormulaC22H31NO3 |
InChIKeyXIQVNETUBQGFHX-UHFFFAOYSA-N |
CAS Registry5633-20-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sialorrhea | Australia | 04 Feb 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sialorrhea | Phase 2 | Japan | - | |
Sialorrhea | Phase 2 | Canada | - | |
Sialorrhea | Phase 2 | South Korea | - | |
Sialorrhea | Phase 2 | United States | - | |
Sialorrhea | Phase 2 | Malaysia | - | |
Sialorrhea | Discovery | United States | - | |
Sialorrhea | Discovery | Malaysia | - | |
Sialorrhea | Discovery | Japan | - | |
Sialorrhea | Discovery | South Korea | - | |
Sialorrhea | Discovery | Canada | - |